Global CAR T Cell Therapy Market, By Targeted Antigen(CD 19,CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll), Therapeutic Application(Acute Lymphocytic, Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
The global CAR T cell therapy market is estimated to be valued at US$ 295.1 million in 2020 and is expected to exhibit a CAGR of 32.5% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
For Requesting a Sample Copy of This Report, Please Visit @
https://www.coherentmarketinsights.com/insight/request-sample/102
Market Overview:
Chimeric antigen receptor (CAR) T cell therapy is a novel immunotherapy used to treat various types of cancers, in which T cells (a type of immune system cells) derived from the patient’s blood are modified in lab with the addition of a special protein receptor on the T-cells that attack cancer cells. It is a way to get immune cells called T cells to fight cancer by finding and destroying cancer cells. The types of cancer that are currently treated using CAR T-cell therapy are B-cell acute lymphoblastic leukemia (ALL), multiple myeloma, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma (DLBCL). The re-engineered T-cells are designed to recognize and attack cancer cells. CAR T cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer.
Key Market Drivers:
Increasing prevalence of cancer, such as multiple myeloma, worldwide is expected to drive growth of the CAR T cell therapy market during the forecast period. For instance, in March 2021, the Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.
Moreover, increase in development of new and effective CAR T cell therapies to treat various types of cancer is expected to boost the growth of the CAR T cell therapy market. For instance, in February 2021, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy for the treatment of large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.
Request a PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/102
COVID-19 Impact Analysis:
The pandemic presents unprecedented challenges to the delivery of cellular therapy to patients with hematologic malignancies (cancers that affect the blood, bone marrow, and lymph nodes). The pandemic has significantly impacted the delivery of cellular therapeutics, including CAR T cells. Moreover, the administration of CAR T cell therapy severely alters patient’s immune system, making them more vulnerable to potential complications of COVID-19. Hematopoietic cell transplant (HCT) and CAR T cell recipients are at higher risk for serious complications of COVID-19, including hospitalization, ICU admissions, and deaths. These recipients are also burdened with other comorbidities associated with COVID-19 related mortality.
Key Takeaways:
The CAR T cell therapy market is expected to exhibit a CAGR of 32.5 % during the forecast period owing to the extensive research for the development of new targeted cell therapies to treat cancer. For instance, in June 2021, Orion Corporation and the Finnish Red Cross Blood Service teamed up to develop CAR T-cell cancer therapy. The research collaboration is based on new innovations to improve the structure of the CAR T-cell product.
Among regions, Asia Pacific is expected to witness robust growth in the CAR T cell therapy market due to the increasing prevalence of cancer and government initiatives to improve health care infrastructure and to develop new and effective cancer therapies. For instance, in June 2021, the Department of Biotechnology, India approved first-in-human Phase I/II clinical trial of the CAR-T cells, for cancer treatment. Moreover, in December 2020, IIT-Bombay (India) scientists developed technology to leverage a patient’s immune system to cure cancer, using CAR T-cells, a treatment for cancer.
North America and Europe are expected to witness significant growth in the CAR T cell therapy market, owing to the increasing prevalence of cancer and extensive research for the development of novel cancer therapies. For instance, in July 2020, Kite, a Gilead Company received FDA approval for Tecartus (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved CA) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Reasons to Purchase this Report
• Current and future of global CAR T cell therapy market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet By Targeted Antigen
- Market Snippet By Therapeutic Application
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Industry Trend
- Epidemiology/Prevalence/Incidence
- Merger and Acquisitions
- New Product Approvals/Launch
- Market Dynamics
- Global Car T Cell Therapy Market, By Targeted Antigen, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, 2017 – 2028
- Segment Trends
- CD 19
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- BCMA
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- HER2
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- GD2
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- CD20
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- CD22
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- CD30
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- CD33
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- HER1
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Car T Cell Therapy Market, By Therapeutic Application, 2017 – 2028 (USD Million)
- Introduction
- Market Share Analysis, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Acute Lymphocytic Leukemia
- Introduction
- Market Share Analysis, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, 2017 – 2028
- Chronic Lymphocytic Leukemia
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Diffuse Large B-cell Lymphoma (DLBCL)
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Follicular Lymphoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Mantle Cell Lymphoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Glioblastoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Sarcoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Neuroblastoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Acute Myeloid Leukemia
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Pancreatic Cancer
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Hepatocellular Carcinoma
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Car T Cell Therapy Market, By Regions, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, For Regions, 2017 – 2028
- North America
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 – 2028
- Market Size and Forecast, By Targeted Antigen, 2017 – 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 – 2028 (US$ Million)
- Europe
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 – 2028
- Market Size and Forecast, By Targeted Antigen, 2017 – 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 – 2028 (US$ Million)
- Asia Pacific
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 – 2028
- Market Size and Forecast, By Targeted Antigen, 2017 – 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 – 2028 (US$ Million)
- Latin America
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 – 2028
- Market Size and Forecast, By Targeted Antigen, 2017 – 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 – 2028 (US$ Million)
- Africa
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 – 2028
- Market Size and Forecast, By Targeted Antigen, 2017 – 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 – 2028 (US$ Million)
- Middle East
- Market Share Analysis, By Segments, 2017 and 2028 (%)
- Y-O-Y Growth Analysis, By Segments, 2017 – 2028
- Market Size and Forecast, By Targeted Antigen, 2017 – 2028 (US$ Million)
- Market Size and Forecast, By Therapeutic Application, 2017 – 2028 (US$ Million)
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profiles
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Kite Pharma, Inc. (Gilead Sciences, Inc.)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Juno Therapeutics (Celgene Corporation)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Bluebird Bio, Inc. (Celgene Corporation)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Sorrento Therapeutics Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Mustang Bio, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Aurora Biopharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Legend Biotech (Genscript Biotech Corporation)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- CARsgen Therapeutics, Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Novartis International AG
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837